Patents by Inventor Leonardo Borras

Leonardo Borras has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stable and soluble antibodies inhibiting VEGF
    Patent number: 12600769
    Abstract: The present invention relates to soluble and stable anti-VEGF imunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
    Type: Grant
    Filed: February 7, 2023
    Date of Patent: April 14, 2026
    Assignee: Novartis AG
    Inventors: Leonardo Borras, David Urech, Tea Gunde
  • COMPLEMENT C3 ANTIGEN BINDING PROTEINS
    Publication number: 20250382357
    Abstract: Antigen-binding proteins with specificity to complement C3 and C3b are provided. Methods of treating complement C3-mediated diseases and disorders, methods of inhibiting the activity of the complement Classical pathway (CP), Lectin pathway (LP), and/or Alternative pathway (AP), and methods of inhibiting the activity of choroidal-localized complement C3 are also provided.
    Type: Application
    Filed: April 3, 2025
    Publication date: December 18, 2025
    Inventors: Leonardo BORRAS, Dominik ESCHER, Stephanie JUNGMICHEL, Christian LEISNER, Philipp Robert RICHLE, Fabian SCHEIFELE
  • ANTI-C3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES
    Publication number: 20250243266
    Abstract: The present invention relates to antibodies and fragments thereof that target the complement C3. More specifically, anti-C3 antibodies and methods of use for the treatment of various diseases or disorders are disclosed.
    Type: Application
    Filed: December 24, 2024
    Publication date: July 31, 2025
    Inventors: Leonardo BORRAS, Pankaj GUPTA, Stefan HOERER, Stephanie JUNGMICHEL, Christian LEISNER, Sophia REINDL, Philipp Robert RICHLE, Fabian SCHEIFELE, Anna SOBIERAJ
  • Anti-C3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
    Patent number: 12344663
    Abstract: The present invention relates to antibodies and fragments thereof that target the complement C3. More specifically, anti-C3 antibodies and methods of use for the treatment of various diseases or disorders are disclosed.
    Type: Grant
    Filed: December 21, 2022
    Date of Patent: July 1, 2025
    Assignees: CDR-Life AG, Boehringer Ingelheim International GmbH
    Inventors: Leonardo Borras, Pankaj Gupta, Stephanie Jungmichel, Christian Leisner, Philipp Robert Richle, Fabian Scheifele, Anna Sobieraj
  • MAGE-A4 PEPTIDE DUAL T CELL ENGAGERS
    Publication number: 20250144141
    Abstract: Described herein are antigen binding proteins with specificity to Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC). Also described are multispecific antigen binding proteins comprising an antigen binding domain with specificity to CD3, and at least one MAGE-A4 pMHC antigen binding domain. Methods of treating cancer with the same are also described.
    Type: Application
    Filed: October 17, 2024
    Publication date: May 8, 2025
    Inventors: Stephanie JUNGMICHEL, Fabian Bert SCHEIFELE, Anna Maria SOBIERAJ, Philipp Robert RICHLE, Hannes MERTEN, Leonardo BORRAS, Christian Valdemar Vinge LEISNER
  • STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF
    Publication number: 20250066462
    Abstract: The present invention relates to soluble and stable anti-VEGF imunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
    Type: Application
    Filed: February 7, 2023
    Publication date: February 27, 2025
    Inventors: Leonardo Borras, David Urech, Tea Gunde
  • DUAL MHC-TARGETING T CELL ENGAGER
    Publication number: 20250002586
    Abstract: Described herein are antigen binding proteins comprising a Fab domain which specifically binds to a cell surface protein of an immune cell, a first pMHC binding domain, and a second pMHC binding domain. Methods of treating cancer or a viral infection with the same are also described.
    Type: Application
    Filed: June 6, 2024
    Publication date: January 2, 2025
    Inventors: Leonardo BORRAS, Stephanie JUNGMICHEL, Hannes MERTEN, Philipp Robert RICHLE, Fabian Bert SCHEIFELE, Anna Maria SOBIERAJ
  • MAGE-A4 peptide dual T cell engagers
    Patent number: 12161673
    Abstract: Described herein are antigen binding proteins with specificity to Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC). Also described are multispecific antigen binding proteins comprising an antigen binding domain with specificity to CD3, and at least one MAGE-A4 pMHC antigen binding domain. Methods of treating cancer with the same are also described.
    Type: Grant
    Filed: September 13, 2023
    Date of Patent: December 10, 2024
    Assignee: CDR-LIFE AG
    Inventors: Stephanie Jungmichel, Fabian Bert Scheifele, Anna Maria Sobieraj, Philipp Robert Richle, Hannes Merten, Leonardo Borras, Christian Valdemar Vinge Leisner
  • MAGE-A4 PEPTIDE-MHC ANTIGEN BINDING PROTEINS
    Publication number: 20240279344
    Abstract: Antigen binding proteins that specifically recognize a target Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC), and nucleic acids encoding the same, are provided. Methods of producing antigen binding proteins that specifically recognize a target MAGE-A4 pMHC, and nucleic acid libraries encoding the same, are also provided.
    Type: Application
    Filed: January 4, 2024
    Publication date: August 22, 2024
    Inventors: Anna Maria Sobieraj, Fabian Bert Scheifele, Stephanie Jungmichel, Leonardo Borras, Christian Valdemar Vinge Leisner
  • MAGE-A4 PEPTIDE DUAL T CELL ENGAGERS
    Publication number: 20240091262
    Abstract: Described herein are antigen binding proteins with specificity to Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC). Also described are multispecific antigen binding proteins comprising an antigen binding domain with specificity to CD3, and at least one MAGE-A4 pMHC antigen binding domain. Methods of treating cancer with the same are also described.
    Type: Application
    Filed: September 13, 2023
    Publication date: March 21, 2024
    Inventors: Stephanie JUNGMICHEL, Fabian Bert SCHEIFELE, Anna Maria SOBIERAJ, Philipp Robert RICHLE, Hannes MERTEN, Leonardo BORRAS, Christian Valdemar Vinge LEISNER
  • MAGE-A4 peptide-MHC antigen binding proteins
    Patent number: 11912771
    Abstract: Antigen binding proteins that specifically recognize a target Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC), and nucleic acids encoding the same, are provided. Methods of producing antigen binding proteins that specifically recognize a target MAGE-A4 pMHC, and nucleic acid libraries encoding the same, are also provided.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: February 27, 2024
    Assignee: CDR-LIFE AG
    Inventors: Anna Maria Sobieraj, Fabian Bert Scheifele, Stephanie Jungmichel, Leonardo Borras, Christian Valdemar Vinge Leisner
  • Humanization of rabbit antibodies using a universal antibody framework
    Patent number: 11858981
    Abstract: The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: January 2, 2024
    Assignee: NOVARTIS AG
    Inventors: Leonardo Borras, David Urech
  • ANTI-C3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES
    Publication number: 20230257455
    Abstract: The present invention relates to antibodies and fragments thereof that target the complement C3. More specifically, anti-C3 antibodies and methods of use for the treatment of various diseases or disorders are disclosed.
    Type: Application
    Filed: December 21, 2022
    Publication date: August 17, 2023
    Inventors: Leonardo BORRAS, Pankaj GUPTA, Stefan HOERER, Stephanie JUNGMICHEL, Christian LEISNER, Sophia REINDL, Philipp Robert RICHLE, Fabian SCHEIFELE, Anna SOBIERAJ
  • Stable and soluble antibodies inhibiting TNF?
    Patent number: 11578123
    Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The antibodies are designed for the diagnosis and/or treatment of TNF-mediated disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of the antibodies in medicine are also described.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: February 14, 2023
    Assignee: Novartis AG
    Inventors: Leonardo Borras, Tea Gunde, David Urech
  • MAGE-A4 PEPTIDE-MHC ANTIGEN BINDING PROTEINS
    Publication number: 20220380472
    Abstract: Antigen binding proteins that specifically recognize a target Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC), and nucleic acids encoding the same, are provided. Methods of producing antigen binding proteins that specifically recognize a target MAGE-A4 pMHC, and nucleic acid libraries encoding the same, are also provided.
    Type: Application
    Filed: March 9, 2022
    Publication date: December 1, 2022
    Inventors: Anna Maria Sobieraj, Fabian Bert Scheifele, Stephanie Jungmichel, Leonardo Borras, Christian Valdemar Vinge Leisner
  • COMPLEMENT C3 ANTIGEN BINDING PROTEINS
    Publication number: 20220259296
    Abstract: Antigen-binding proteins with specificity to complement C3 and C3b are provided. Methods of treating complement C3-mediated diseases and disorders, methods of inhibiting the activity of the complement Classical pathway (CP), Lectin pathway (LP), and/or Alternative pathway (AP), and methods of inhibiting the activity of choroidal-localized complement C3 are also provided.
    Type: Application
    Filed: February 11, 2022
    Publication date: August 18, 2022
    Inventors: Leonardo BORRAS, Dominik ESCHER, Stephanie JUNGMICHEL, Christian LEISNER, Philipp Robert RICHLE, Fabian SCHEIFELE
  • Solubility optimization of immunobinders
    Patent number: 11046757
    Abstract: The invention provides methods of using sequence based analysis and rational strategies to improve the solubility of immunobinders, and in particular of single chain antibodies (scFvs). The invention provides methods of engineering immunobinders, and in particular scFvs, by performing one or more substitutions with hydrophilic residues identified by analysis of a database of selected, stable scFv sequences. The invention also provides immunobinders with optimized solubility prepared according to the engineering methods of the invention.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: June 29, 2021
    Assignee: NOVARTIS AG
    Inventors: Leonardo Borras, David Urech
  • Method for decreasing immunogenicity
    Patent number: 10781268
    Abstract: A method for decreasing the immunogenicity of antibody variable domains is disclosed.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: September 22, 2020
    Assignee: Novartis AG
    Inventors: David Urech, Leonardo Borras
  • Stable and soluble antibodies inhibiting VEGF
    Patent number: 10590193
    Abstract: The present invention relates to soluble and stable anti-VEGF imunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: March 17, 2020
    Assignee: Novartis AG
    Inventors: Leonardo Borras, David Urech, Tea Gunde
  • TRISPECIFIC ANTIGEN BINDING PROTEINS
    Publication number: 20200062858
    Abstract: Trispecific antigen-binding proteins including: a first binding domain capable of binding to a cell surface protein of a tumor cell; a second binding domain capable of binding to a cell surface immune checkpoint protein of the tumor cell; and a third binding domain capable of binding to a cell surface protein of an immune cell, are provided. Methods of making trispecific antigen-binding proteins are provided.
    Type: Application
    Filed: August 5, 2019
    Publication date: February 27, 2020
    Inventors: Leonardo BORRAS, Thomas SCHLEIER, Philipp Robert RICHLE, Dominik ESCHER, Christian Valdemar Vinge LEISNER, Fabian SCHEIFELE